Vaccination with genetically engineered allergens prevents progression of allergic disease

AUTOR(ES)

Niederberger, V.

FONTE

National Academy of Sciences

RESUMO

IgE-mediated allergy affects >25% of the population in industrialized countries. Repeated contact with the disease-eliciting allergens induces rises of allergen-specific IgE Abs and progression of the disease to more severe manifestations. Our study uses a type of vaccine that is based on genetically modified allergen derivatives to treat allergic patients. We developed hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, by genetic engineering and vaccinated birch pollen-allergic patients (n = 124) in a double-blind, placebo-controlled study. Active treatment induced protective IgG Abs that inhibited allergen-induced release of inflammatory mediators. We also observed a reduction of cutaneous sensitivity as well as an improvement of symptoms in actively treated patients. Most important, rises of allergen-specific IgE induced by seasonal birch pollen exposure were significantly reduced in vaccinated patients. Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease.

Documentos Relacionados

• Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine.
• Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
• Genetically engineered broad-spectrum disease resistance in tomato
• Vaccination with an attenuated Creutzfeldt–Jakob disease strain prevents expression of a virulent agent
• Chilling sensitivity of Arabidopsis thaliana with genetically engineered membrane lipids.